Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and β1 integrin/FAK−mediated signalling
Klobučar, M., Grbčić, P., Pavelić, S. K., Jonjić, N., Visentin, S. & Sedić, M. (2018). Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and β1 integrin/FAK−mediated signalling. Biochemical and Biophysical Research Communications, 503. (2), 843-848. doi: 10.1016/j.bbrc.2018.06.085
Klobučar, Marko, et al. "Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and β1 integrin/FAK−mediated signalling." Biochemical and Biophysical Research Communications, vol. 503, no. 2, 2018, pp. 843-848. https://doi.org/10.1016/j.bbrc.2018.06.085
Klobučar, Marko, Petra Grbčić, Sandra Kraljević Pavelić, Nives Jonjić, Sarah Visentin and Mirela Sedić. "Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and β1 integrin/FAK−mediated signalling." Biochemical and Biophysical Research Communications 503, no. 2 (2018): 843-848. https://doi.org/10.1016/j.bbrc.2018.06.085
Klobučar, M., et al. (2018) 'Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and β1 integrin/FAK−mediated signalling', Biochemical and Biophysical Research Communications, 503(2), pp. 843-848. doi: 10.1016/j.bbrc.2018.06.085
Klobučar M, Grbčić P, Pavelić SK, Jonjić N, Visentin S, Sedić M. Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and β1 integrin/FAK−mediated signalling. Biochemical and Biophysical Research Communications [Internet]. 2018 September [cited 2024 December 06];503(2):843-848. doi: 10.1016/j.bbrc.2018.06.085
M. Klobučar, P. Grbčić, S. K. Pavelić, N. Jonjić, S. Visentin and M. Sedić, "Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and β1 integrin/FAK−mediated signalling", Biochemical and Biophysical Research Communications, vol. 503, no. 2, pp. 843-848, September 2018. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:385873. [Accessed: 06 December 2024]